News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , March 19, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with
View HTML
Toggle Summary Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported pipeline highlights and financial results for
View HTML
Toggle Summary Ardelyx Announces Departure of Chief Scientific Officer
FREMONT, Calif. , Feb. 12, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell , Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018 , to pursue a position as chief executive officer of an early stage biotech start-up company
View HTML
Toggle Summary Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
FREMONT, Calif. , Feb. 8, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb.
View HTML
Toggle Summary Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT .
View HTML
Toggle Summary Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Favorable Tolerability Profile Demonstrated in 1-year Safety Study FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of
View HTML
Toggle Summary Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Ardelyx to Receive Up to $125 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company
View HTML
Toggle Summary Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Ardelyx to Receive a $30 Million Upfront Payment and Subsequent Milestones FREMONT, Calif. and TOKYO , Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, " Kyowa Hakko Kirin "), today announced that they have entered into a license agreement
View HTML
Toggle Summary Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Company to Host Conference Call at 8:30 a.m. ET Today FREMONT, Calif. , Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
FREMONT, Calif. , Nov. 7, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017 . "2017 has been a landmark year for Ardelyx , with three statistically significant Phase 3
View HTML